3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
CNS
1
Breast
1
Conditions
Glioblastoma
40
Glioma
17
Brain Neoplasms
14
Astrocytoma
11
Neuroblastoma
10
Gliosarcoma
10
Neoplasms
8
Sarcoma, Ewing
7
Rhabdomyosarcoma
6
Recurrence
5
Oligodendroglioma
5
Sarcoma
4
Medulloblastoma
4
Neoplasm Metastasis
3
Diffuse Intrinsic Pontine Glioma
3
Wilms Tumor
2
Small Cell Lung Carcinoma
2
Pancreatic Neoplasms
2
Osteosarcoma
2
Melanoma
2
Lymphoma, Follicular
2
Hepatoblastoma
2
Central Nervous System Neoplasms
2
Spinal Cord Neoplasms
1
Somatostatinoma
1
Rhabdoid Tumor
1
Refractory Solid Tumors
1
Pyloric Stenosis, Hypertrophic
1
Prostatic Neoplasms
1
Pheochromocytoma
1
Interventions
Magnetic Resonance Spectroscopy
47
enzalutamide
46
apalutamide
36
Specimen Handling
30
Androgen Antagonists
30
Abiraterone Acetate
29
Radiosurgery
26
Prednisone
25
darolutamide
24
Docetaxel
23
Pluvicto
21
abiraterone
19
Radiotherapy
19
Biopsy
17
Leuprolide
15
Surveys and Questionnaires
11
Radiation
11
2-(3-(1-carboxy-5-((6-fluoropyridine-3-carbonyl)amino)pentyl)ureido)pentanedioic acid
11
relugolix
10
gallium 68 PSMA-11
10
acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide
10
Standard of Care
10
Nivolumab
10
cabazitaxel
9
Triptorelin Pamoate
9
bicalutamide
8
Carboplatin
8
pembrolizumab
7
olaparib
7
niraparib
7
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Prostatic Neoplasms
×
Temozolomide
×
90 days
×
Clear all
NCT05417594
2026-06-02
CERTIS1
AstraZeneca
Phase 1/2
Recruiting
695 enrolled